SToRytelling to Improve Disease outcomes in Gout (STRIDE-GO): a multicenter, randomized controlled trial in African American veterans with gout

Abstract Background Urate-lowering therapy (ULT) adherence is low in gout, and few, if any, effective, low-cost, interventions are available. Our objective was to assess if a culturally appropriate gout-storytelling intervention is superior to an attention control for improving gout outcomes in Afri...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jasvinder A. Singh, Amy Joseph, Joshua Baker, Joshua S. Richman, Terrence Shaneyfelt, Kenneth G. Saag, Seth Eisen
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Gout Adherence Trial Storytelling Randomized controlled trial Urate-lowering therapy Medicine R
Acceso en línea:	https://doaj.org/article/e9928a925ae743c3a13fba0208525887
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e9928a925ae743c3a13fba0208525887
record_format	dspace
spelling	oai:doaj.org-article:e9928a925ae743c3a13fba02085258872021-11-14T12:17:11ZSToRytelling to Improve Disease outcomes in Gout (STRIDE-GO): a multicenter, randomized controlled trial in African American veterans with gout10.1186/s12916-021-02135-w1741-7015https://doaj.org/article/e9928a925ae743c3a13fba02085258872021-11-01T00:00:00Zhttps://doi.org/10.1186/s12916-021-02135-whttps://doaj.org/toc/1741-7015Abstract Background Urate-lowering therapy (ULT) adherence is low in gout, and few, if any, effective, low-cost, interventions are available. Our objective was to assess if a culturally appropriate gout-storytelling intervention is superior to an attention control for improving gout outcomes in African-Americans (AAs). Methods In a 1-year, multicenter, randomized controlled trial, AA veterans with gout were randomized to gout-storytelling intervention vs. a stress reduction video (attention control group; 1:1 ratio). The primary outcome was ULT adherence measured with MEMSCap™, an electronic monitoring system that objectively measured ULT medication adherence. Results The 306 male AA veterans with gout who met the eligibility criteria were randomized to the gout-storytelling intervention (n = 152) or stress reduction video (n = 154); 261/306 (85%) completed the 1-year study. The mean age was 64 years, body mass index was 33 kg/m2, and gout disease duration was 3 years. ULT adherence was similar in the intervention vs. control groups: 3 months, 73% versus 70%; 6 months, 69% versus 69%; 9 months, 66% versus 67%; and 12 months, 61% versus 64% (p > 0.05 each). Secondary outcomes (gout flares, serum urate and gout-specific health-related quality of life [HRQOL]) in the intervention versus control groups were similar at all time points except intervention group outcomes were better for the following: (1) number of gout flares at 9 months were fewer, 0.7 versus 1.3 in the previous month (p = 0.03); (2) lower/better scores on two gout specific HRQOL subscales: gout medication side effects at 3 months, 32.8 vs. 39.6 (p = 0.02); and unmet gout treatment need at 3 months, 30.9 vs. 38.2 (p = 0.003), and 6 months, 29.5 vs. 34.5 (p = 0.03), respectively. Conclusions A culturally appropriate gout-storytelling intervention was not superior to attention control for improving gout outcomes in AAs with gout. Trial registration Registered at ClinicalTrials.gov NCT02741700Jasvinder A. SinghAmy JosephJoshua BakerJoshua S. RichmanTerrence ShaneyfeltKenneth G. SaagSeth EisenBMCarticleGoutAdherenceTrialStorytellingRandomized controlled trialUrate-lowering therapyMedicineRENBMC Medicine, Vol 19, Iss 1, Pp 1-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Gout Adherence Trial Storytelling Randomized controlled trial Urate-lowering therapy Medicine R
spellingShingle	Gout Adherence Trial Storytelling Randomized controlled trial Urate-lowering therapy Medicine R Jasvinder A. Singh Amy Joseph Joshua Baker Joshua S. Richman Terrence Shaneyfelt Kenneth G. Saag Seth Eisen SToRytelling to Improve Disease outcomes in Gout (STRIDE-GO): a multicenter, randomized controlled trial in African American veterans with gout
description	Abstract Background Urate-lowering therapy (ULT) adherence is low in gout, and few, if any, effective, low-cost, interventions are available. Our objective was to assess if a culturally appropriate gout-storytelling intervention is superior to an attention control for improving gout outcomes in African-Americans (AAs). Methods In a 1-year, multicenter, randomized controlled trial, AA veterans with gout were randomized to gout-storytelling intervention vs. a stress reduction video (attention control group; 1:1 ratio). The primary outcome was ULT adherence measured with MEMSCap™, an electronic monitoring system that objectively measured ULT medication adherence. Results The 306 male AA veterans with gout who met the eligibility criteria were randomized to the gout-storytelling intervention (n = 152) or stress reduction video (n = 154); 261/306 (85%) completed the 1-year study. The mean age was 64 years, body mass index was 33 kg/m2, and gout disease duration was 3 years. ULT adherence was similar in the intervention vs. control groups: 3 months, 73% versus 70%; 6 months, 69% versus 69%; 9 months, 66% versus 67%; and 12 months, 61% versus 64% (p > 0.05 each). Secondary outcomes (gout flares, serum urate and gout-specific health-related quality of life [HRQOL]) in the intervention versus control groups were similar at all time points except intervention group outcomes were better for the following: (1) number of gout flares at 9 months were fewer, 0.7 versus 1.3 in the previous month (p = 0.03); (2) lower/better scores on two gout specific HRQOL subscales: gout medication side effects at 3 months, 32.8 vs. 39.6 (p = 0.02); and unmet gout treatment need at 3 months, 30.9 vs. 38.2 (p = 0.003), and 6 months, 29.5 vs. 34.5 (p = 0.03), respectively. Conclusions A culturally appropriate gout-storytelling intervention was not superior to attention control for improving gout outcomes in AAs with gout. Trial registration Registered at ClinicalTrials.gov NCT02741700
format	article
author	Jasvinder A. Singh Amy Joseph Joshua Baker Joshua S. Richman Terrence Shaneyfelt Kenneth G. Saag Seth Eisen
author_facet	Jasvinder A. Singh Amy Joseph Joshua Baker Joshua S. Richman Terrence Shaneyfelt Kenneth G. Saag Seth Eisen
author_sort	Jasvinder A. Singh
title	SToRytelling to Improve Disease outcomes in Gout (STRIDE-GO): a multicenter, randomized controlled trial in African American veterans with gout
title_short	SToRytelling to Improve Disease outcomes in Gout (STRIDE-GO): a multicenter, randomized controlled trial in African American veterans with gout
title_full	SToRytelling to Improve Disease outcomes in Gout (STRIDE-GO): a multicenter, randomized controlled trial in African American veterans with gout
title_fullStr	SToRytelling to Improve Disease outcomes in Gout (STRIDE-GO): a multicenter, randomized controlled trial in African American veterans with gout
title_full_unstemmed	SToRytelling to Improve Disease outcomes in Gout (STRIDE-GO): a multicenter, randomized controlled trial in African American veterans with gout
title_sort	storytelling to improve disease outcomes in gout (stride-go): a multicenter, randomized controlled trial in african american veterans with gout
publisher	BMC
publishDate	2021
url	https://doaj.org/article/e9928a925ae743c3a13fba0208525887
work_keys_str_mv	AT jasvinderasingh storytellingtoimprovediseaseoutcomesingoutstridegoamulticenterrandomizedcontrolledtrialinafricanamericanveteranswithgout AT amyjoseph storytellingtoimprovediseaseoutcomesingoutstridegoamulticenterrandomizedcontrolledtrialinafricanamericanveteranswithgout AT joshuabaker storytellingtoimprovediseaseoutcomesingoutstridegoamulticenterrandomizedcontrolledtrialinafricanamericanveteranswithgout AT joshuasrichman storytellingtoimprovediseaseoutcomesingoutstridegoamulticenterrandomizedcontrolledtrialinafricanamericanveteranswithgout AT terrenceshaneyfelt storytellingtoimprovediseaseoutcomesingoutstridegoamulticenterrandomizedcontrolledtrialinafricanamericanveteranswithgout AT kennethgsaag storytellingtoimprovediseaseoutcomesingoutstridegoamulticenterrandomizedcontrolledtrialinafricanamericanveteranswithgout AT setheisen storytellingtoimprovediseaseoutcomesingoutstridegoamulticenterrandomizedcontrolledtrialinafricanamericanveteranswithgout
_version_	1718429322011738112

SToRytelling to Improve Disease outcomes in Gout (STRIDE-GO): a multicenter, randomized controlled trial in African American veterans with gout

Ejemplares similares